Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions. Issue 4 (24th March 2022)

• Record Type: Journal Article
• Authors: Waite, Kristin A; Cioffi, Gino; Kruchko, Carol; Patil, Nirav; Brat, Daniel J; Bruner, Janet M; McLendon, Roger E; Tihan, Tarik; Ostrom, Quinn T; Barnholtz-Sloan, Jill S
• Is Part Of: Neuro-oncology practice. Volume 9:Issue 4(2022)
• Page Start: 317
• Page End: 327
• Publication Date: 2022-03-24
• Subjects: brain tumors -- epidemiology -- histology -- CBTRUS; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481005
• DOI: 10.1093/nop/npac025
• Languages: English
• ISSNs: 2054-2577

Abstract

Abstract: Background: The Central Brain Tumor Registry of the United States (CBTRUS) uses a histology grouping model based on the World Health Organization (WHO) classifications to group records for clinically relevant statistical reporting. Newly identified genetic markers more accurately stratify patients than histology alone and were incorporated into the 2016 update to the WHO Classification. Methods: CBTRUS and consulting neuropathologists reviewed and aligned histology groupings with the 2016 WHO update. "Obsolete" (terms not currently in use) histology nomenclature along with their International Classification of Disease, Oncology 3rd edition (ICD-O-3) codes were identified, some histologies were reclassified to 2016 WHO, and new codes found in 2016 WHO were incorporated. An evaluation of the frequency of histology codes affected in the realignment process, and incidence and survival pre- and post-realignment was conducted. Results: After review, 67 codes were noted as obsolete, 51 codes were reclassified, and 12 new codes were incorporated. Histology groups most affected were mesenchymal tumors and neuronal/mixed neuronal-glial tumors. Reorganization resulted in 2588 (0.65%) cases with grouping reassignment or reporting change, indicating that the 2016 WHO Classification revision has impacted the collection and reporting of primary brain and other CNS tumors. Conclusion: This work demonstrates the need to be responsive to changes in classification and coding in order to ensure the most up-to-date and accurate statistics for brain and CNS tumors. This will require collaboration from all stakeholders within the brain tumor community, so to have the ability to reconcile clinical practices and surveillance requirements.